James Guevara-Pulido

Dr. James Guevara-Pulido

Pharmaceutical Chemistry, Universidad El Bosque, Bogotá, Colombia
orcid
Drug Discovery

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in ChemistrySelect
Verified
Journal Article
Closed access
James Guevara-PulidoJames Guevara-Pulido
James Guevara-Pulido
RJRonald Jiménez
Ronald Jiménez
SMSandra J. Morantes
Sandra J. Morantes
DJDeissy N. Jaramillo
Deissy N. Jaramillo
PAPaola Acosta‐Guzmán
Paola Acosta‐Guzmán

27 August 2014 in The Journal of Organic Chemistry
Verified
Journal Article
Open access
James Guevara-PulidoJames Guevara-Pulido
James Guevara-Pulido
JAJose M. Andres
Jose M. Andres
RPRafael Pedrosa
Rafael Pedrosa
Enantioenriched trisubstituted lactones were obtained in good yields and moderate to very good enantioselectivities in one-pot process, which implies a sequential organocatalyzed Michael addition of ketones to enals, followed by catalytic intramolecular diastereoselective Tishchenko reaction and lactonization. The final lactones were obtained as single diastereoisomers, demonstrating that the mixture of the anti and syn diastereomers epimerized to the syn hydroxy ester during the oxido-reduction step.


8 February 2023 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
DJDeissy N. Jaramillo
Deissy N. Jaramillo
DMDiana Millán
Diana Millán
James Guevara-PulidoJames Guevara-Pulido
James Guevara-Pulido
Depression is one of the most common mental illnesses, affecting almost 300 million people. According to the WHO, depression is one of the world's leading causes of disability and morbidity. People with this illness require both psychological and pharmaceutical treatment because severe depressive episodes often result in suicide. Selective serotonin reuptake inhibitors (SSRI) are widely used antidepressants that target the human serotonin transporter (hSERT). The crystallization of hSERT and the experimental data available allows cost and time-efficient computational tools like virtual screening (VS) to be utilized in the development of therapeutic agents. Here, we synthesized, characterized, and evaluated the biological activity of a novel SSRI analog of paroxetine, rationally designed by applying an artificial neural network-based QSAR model and a molecular docking analysis on hSERT. The analog N-substituted 18a showed higher affinity for the transporter (-10.2 kcal/mol), lower Ki value (1.19 nM) and a safer toxicological profile than paroxetine and was synthesized with a 71% yield. The in vitro cytotoxicity of the analog was evaluated using human glioblastoma (U87 MG), human neuroblastoma (SH SY5Y) and murine fibroblast (L929) cell lines. Also, the hemolytic ability of the compound was assessed on human erythrocytes. Results showed that analog 18a did not exhibit cytotoxic activity on the cell lines used and has no hemolytic activity at any of the concentrations tested, whereas with paroxetine, hemolysis was observed at 2.3, 1.29 y 0.67 mM. Based on these results, it is possible to suggest that analog 18a could be a promising new SSRI candidate for the treatment of this illness.

17 February 2024 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
MPMariana Prieto
Mariana Prieto
ANAngelica Niño
Angelica Niño
PAPaola Acosta-Guzmán
Paola Acosta-Guzmán
James Guevara-PulidoJames Guevara-Pulido
James Guevara-Pulido

1 January 2020 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
JAJhon Alex Gonzalez Amaya
Jhon Alex Gonzalez Amaya
DCDaniella Zambrano Cabrera
Daniella Zambrano Cabrera
AMAlejandra Mojica Matallana
Alejandra Mojica Matallana
KAKaren González Arevalo
Karen González Arevalo
James Guevara-PulidoJames Guevara-Pulido
James Guevara-Pulido